Co-treatment of trametinib (MEK inhibitor) with TPX-0005 (Src/FAK/JAK2 inhibitor) synergistic in KRAS mutant NSCLC cell lines and CDCP1 acts as a biomarker in KRAS mutant patients (p)

被引：0
|
作者：
Codony-Servat, C. [1 ]
Gil Moreno, M. Llanos [2 ]
Bracht, J. [1 ]
Attili, I. [3 ]
Lazzari, C. [4 ]
Gregorc, V. [5 ]
Ito, M. [6 ]
Viteri, S. [7 ]
Karachaliou, N. [8 ]
Rosell, R. [9 ]
机构：
[1] Quiron Dexeus Univ Inst, IOR, Coyote Res Grp, Pangaea Oncol, Barcelona, Spain
[2] Dr Rosell Hosp Univ Quiron Dexeus, Inst Oncol, Barcelona, Spain
[3] IRCCS, Ist Oncol Veneto, Padua, Italy
[4] Ist Europeo Oncol, Milan, Italy
[5] IRCCS San Raffaele, Milan, Italy
[6] Hiroshima Univ, Surg Oncol, Hiroshima, Japan
[7] Hosp Univ Quiron Dexeus, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[8] Hosp Sagrado Corazon, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[9] Hosp Badalona Germans Trias & Pujol, Canc Biol & Precis Med Program, Germans Trias & Pujol Sci Inst, Catalan Inst Oncol ICO Badalona, Badalona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(18)30334-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58P
引用
收藏
页码：S30 / S31
页数：2
相关论文
共 7 条
  • [1] Repotrectinib increases effectiveness of MEK inhibitor trametinib in KRAS mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition
    Murray, Brion
    Deng, Wei
    Zhai, Dayong
    Rodon, Laura
    Lee, Nathan
    Cui, J. Jean
    CANCER RESEARCH, 2020, 80 (16)
  • [2] A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
    Blumenschein, G. R., Jr.
    Smit, E. F.
    Planchard, D.
    Kim, D. -W.
    Cadranel, J.
    De Pas, T.
    Dunphy, F.
    Udud, K.
    Ahn, M. -J.
    Hanna, N. H.
    Kim, J. -H.
    Mazieres, J.
    Kim, S. -W.
    Baas, P.
    Rappold, E.
    Redhu, S.
    Puski, A.
    Wu, F. S.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 894 - 901
  • [3] ORAL MEK1/MEK2 INHIBITOR TRAMETINIB (GSK1120212) IN COMBINATION WITH DOCETAXEL IN A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS
    Bennouna, Jaafar
    Leighl, Natasha B.
    Kelly, Karen
    Blumenschein, George R.
    Zalcman, Gerard
    Audebert, Christine
    Gomez-Roca, Carlos
    Reckamp, Karen L.
    Infante, Jeffrey R.
    Lara, Primo
    Shepherd, Frances A.
    Janku, Filip
    Cho, Byoung Chul
    Park, Keunchil
    Braiteh, Fadi S.
    Jotte, Robert M.
    Wu, Yuehui
    Schramek, Daniel J.
    Cox, Donna S.
    Piepszak, Alexandra M.
    Liu, Yuan
    Gardner, Olivia S.
    Peddareddigari, Vijay G. R.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S370 - S371
  • [4] ORAL MEK1/MEK2 INHIBITOR TRAMETINIB (GSK1120212) IN COMBINATION WITH PEMETREXED IN A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS
    Mazieres, Julien
    Gandara, David R.
    Leighl, Natasha B.
    Wheler, Jennifer J.
    Barlesi, Fabrice
    Zalcman, Gerard
    Kelly, Karen
    Reckamp, Karen L.
    Gordon, Michael S.
    Hiret, Sandrine
    Shepherd, Frances A.
    Janku, Filip
    Cho, Byoung Chul
    Park, Keunchil
    Infante, Jeffrey R.
    Richards, Donald A.
    Wu, Yuehui
    Schramek, Daniel J.
    Cox, Donna S.
    Piepszak, Alexandra M.
    Liu, Yuan
    Gardner, Olivia S.
    Peddareddigari, Vijay G. R.
    Blumenschein, George R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S369 - S370
  • [5] Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
    Kelly, Karen
    Mazieres, Julien
    Leighl, Natasha B.
    Barlesi, Fabrice
    Zalcman, Gerard
    Gordon, Michael S.
    Reckamp, Karen L.
    Gandara, David R.
    Gomez-Roca, Carlos Alberto
    Bennouna, Jaafar
    Cho, Byoung Chul
    Park, Keunchil
    Infante, Jeffrey R.
    Richards, Donald A.
    Wu, Yuehui
    Schramek, Daniel J.
    Cox, Donna S.
    Gardner, Olivia S.
    Peddareddigari, Vijay Gopal Reddy
    Blumenschein, George R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
    Gandara, David R.
    Hiret, Sandrine
    Blumenschein, George R.
    Barlesi, Fabrice
    Delord, Jean-Pierre
    Madelaine, Jeannick
    Infante, Jeffrey R.
    Reckamp, Karen L.
    Lara, Primo
    Audebert, Christine
    Cho, Byoung Chul
    Park, Keunchil
    Braiteh, Fadi S.
    Jotte, Robert M.
    Wu, Yuehui
    Schramek, Daniel J.
    Piepszak, Alexandra M.
    Gardner, Olivia S.
    Peddareddigari, Vijay Gopal Reddy
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Awad, Mark M.
    Gadgeel, Shirish M.
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
1